UNITED STATES
               SECURITIES AND EXCHANGE COMMISSION
                      WASHINGTON, DC 20549


                            FORM 8-K/A


                         CURRENT REPORT
             Pursuant to Section 13 or 15(d) of the
                 Securities Exchange Act of 1934

Date of report (Date of earliest event reported):
                  November 26, 2007

                        JOHNSON & JOHNSON
     (Exact name of registrant as specified in its charter)

     New Jersey             1-3215        22-1024240
(State or Other Juris-   (Commission    (IRS Employer
diction of Incorporation) File Number  Identification No.)


  One Johnson & Johnson Plaza, New Brunswick, New Jersey 08933
       (Address of Principal Executive Offices) (Zip Code)

Registrant's telephone number, including area code:  732-524-0400

      Check  the appropriate box below if the Form 8-K filing  is
intended to simultaneously satisfy the filing obligation  of  the
registrant under any of the following provisions:

     [   ]  Written communications pursuant to Rule 425 under the
     Securities Act (17 CFR 230.425)

     [   ]  Soliciting material pursuant to Rule 14a-12 under the
     Exchange Act (17 CFR 240.14a-12)

     [   ]  Pre-commencement communications pursuant to Rule 14d-
     2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     [   ]  Pre-commencement communications pursuant to Rule 13e-
     4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.06.  Material Impairments.

On November 29, 2007, Johnson & Johnson (the "Company")
announced that it will record a special after-tax, non-cash
charge of approximately $440 million for the write-down of the
intangible asset related to NATRECORr (nesiritide), a product for
the treatment of patients with acutely decompensated heart
failure who have dyspnea at rest or with minimal activity.
Management concluded that this charge is required under generally
accepted accounting principles in the United States on November
26, 2007.  This charge results from revised estimates of future
cash flows from this product due primarily to a recent decline in
NATRECORr sales trends.  Management believes that NATRECORr is an
important clinical option for the treatment of acutely
decompensated heart failure and the product will continue to be
marketed by Scios Inc., a subsidiary of the Company. The impact
of this special item will be reflected in the Company's fourth
quarter 2007 results.

Special items, such as this, do not impact the Company's earnings
per share guidance, which excludes the impact of in-process
research and development ("IPR&D") charges, restructuring charges
and other special items.

Item 8.01.  Other Events.

On November 29, 2007, the Company announced that it will record a
special tax gain of approximately $260 million associated with
the restructuring of certain international subsidiaries.  The
relevant government authorities approved this restructuring in
the fourth quarter of 2007.

Special items, such as this, do not impact the Company's earnings
per share guidance, which excludes the impact of IPR&D charges,
restructuring charges and other special items.

                           SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed
on its behalf by the undersigned hereunto duly authorized.

                              JOHNSON & JOHNSON
                              (Registrant)


Date:  November 29, 2007     By: /s/ S. J. COSGROVE
                                S. J. Cosgrove
                                Controller
                                (Principal Accounting Officer)